Human liver stem cells and derived extracellular vesicles improve recovery in a murine model of acute kidney injury

Maria Beatriz Herrera Sanchez1, Stefania Bruno2, Cristina Grange3, Marta Tapparo3, Vincenzo Cantaluppi3, Ciro Tetta4 and Giovanni Camussi3*

Abstract

Introduction: Several cellular sources of stem cells have been tested in the attempt to yield innovative interventions in acute kidney injury (AKI). Human liver stem cells (HLSCs) are cells isolated from the normal adult human liver which are gaining attention for their therapeutic potential. In the present study, we investigated whether HLSCs and the derived extracellular vesicles may promote tubular regeneration after AKI induced by glycerol injection in severe-combined immune-deficient mice.

Methods: HLSCs were expanded and conditioned medium (CM) and extracellular vesicles (EVs) were purified. HLSCs and their bioproducts were tested in a model of AKI induced by intra-muscle glycerol injection. Renal function and morphology were evaluated five days after induction of damage. The effect of EVs on proliferation and apoptosis of murine renal tubular cells was tested in vitro.

Results: We found that intravenous injection of 3.5×10^5 HLSCs into mice three days after induction of AKI significantly improved functional and morphological recovery. The injection of HLSCs decreased creatinine and urea, as well as hyaline cast formation, tubular necrosis and enhanced in vivo tubular cell proliferation. The effect of soluble factors release by HLSCs in the regenerative processes was also studied. CM produced by HLSCs, mimicked the effect of the cells. However, depletion of EVs significantly reduced the functional and morphological recovery of CM. Moreover, we found that purified HLSC-derived EVs ameliorated renal function and morphology in a manner comparable to the cells. In vitro HLSC-derived EVs were shown to stimulate proliferation and inhibit apoptosis of murine renal tubular cells.

Conclusions: These results indicate that HLSCs increase recovery after AKI. EVs are the main component of HLSC-derived CM capable of promoting regeneration in experimental AKI.

Introduction

We recently identified and characterized adult human liver stem cells (HLSCs) [1]. HLSCs expressed markers characteristic of the mesenchymal lineage together with albumin and alpha-fetoprotein, suggesting a partial hepatic commitment but lack of hematopoietic stem markers. HLSCs were also able to undergo multiple in vitro differentiations. In vivo, we demonstrated the therapeutic potential of HLSCs in several experimental models of liver injury [1,2]. We found that HLSCs contribute to regeneration of the liver parenchyma in acetaminophen induced-injury [1] and significantly attenuate mouse mortality in a model of fulminant liver failure in severe-combined immune-deficient (SCID) mice [2]. It has been recently suggested that the biological effects of stem cells are mediated by paracrine factors acting on neighboring cells [3,4]. Indeed, Bi et al. showed that conditioned medium (CM) derived from mesenchymal stem cells (MSCs) diminishes the apoptosis of tubular cells and limits renal injury [5] in a model of acute kidney injury (AKI) induced by cisplatin. Similarly, in a model of fulminant hepatic injury induced by D-galactosamine and lipopolysaccharide, we found that CM from HLSCs mimicked the beneficial effect of cells [2]. In addition to soluble factors, extracellular vesicles (EVs) released...
from stem cells have been shown to contribute to renal recovery after AKI [6,7].

A seminal work of De Broe et al. [8] demonstrated that cell-derived circular plasma-membrane fragments retained an enzymatic activity similar to that of the originating cells. Subsequent studies demonstrated that EVs play a critical role as mediators of cell-to-cell communication [9]. Bruno et al. [6] showed that EVs released from MSCs promoted the recovery from AKI, stimulated a proliferative program in tubular epithelial cells and reduced lethality in SCID mice treated with cisplatin [10]. Similarly, EVs derived from MSCs reduced injury and stimulated recovery in a model of renal ischemia/reperfusion [7]. We found that, HLSC-derived EVs induced in vitro proliferation and apoptosis resistance of human and rat hepatocytes and accelerated in vivo the morphological and functional recovery of the liver in a model of 70% hepatectomy in rats [11].

The therapeutic potential of HLSCs in diseased organs different from the liver has not yet been evaluated. The aim of the present study was to investigate whether HLSCs, HLSC-derived CM and HLSC-derived EVs contribute to tubular regeneration in AKI induced in mice by intramuscular injection of glycerol in SCID.

Methods

Isolation and characterization of HLSCs

HLSCs were isolated from human cryopreserved normal adult hepatocytes (Lonza, Basel, Switzerland). The isolation, culture and characterization of HLSCs were performed as previously described [1]. Briefly, hepatocytes were initially cultured for two weeks in Hepatozyme-SFM medium. After the two weeks, most hepatocytes died, and then the medium was substituted by α-MEM/EBM-1 (3:1) (Invitrogen, Carlsbad, CA, USA) media supplemented with l-glutamine (5 mM), Hepes (12 mM, pH 7.4), penicillin (50 IU/ml), streptomycin (50 μg/ml) (all from Sigma, St. Louis, MO, USA) and fetal calf serum (FCS) (10%) (Invitrogen). Cells were expanded and characterized. HLSCs expressed the mesenchymal stem cell markers but not the hematopoietic and endothelial markers as described above. HLSCs were also positive for human albumin and alpha-fetoprotein and for the resident stem cells markers vimentin and nestin, and were negative for CD34, CD117 and cytokeratin 19 oval cell markers [1]. HLSCs also expressed the embryonic stem cell markers nanog, Oct4, Sox2 and SSEA4 [2]. HLSCs were shown to undergo osteogenic, endothelial and hepatic differentiation under appropriate culture conditions [1].

Isolation of HLSC-derived EVs

EVs were obtained from supernatants of HLSCs (2 × 10^6 cells/T75) cultured for 24 hours in Roswell Park Memorial Institute medium (RPMI) deprived of FCS. The viability of HLSCs at the time of EV collection was 97% to 99% as detected by trypan blue exclusion and no apoptotic cells were detectable by TUNEL assay.

After removal of cell debris and apoptotic bodies by two centrifugations at 3,000 g for 20 minutes, EVs were purified by two hours ultracentrifugation (100,000 g) at 4°C (Beckman Coulter Optima L-90 K, Fullerton, CA, USA). EVs were used fresh or stored at ~80°C after resuspension in RPMI supplemented with 5% dimethyl sulfoxide (DMSO). No difference in biological activity was observed between fresh and stored EVs.

To trace EVs by fluorescent microscopy, EVs were labeled with 1 μM Dil dye (Molecular Probes, Life Technology, NY, NY, USA) during ultracentrifugation [12]. After labeling, EVs were washed by ultracentrifugation at 100,000 g for one hour at 4°C. EV pellets were suspended in (D)MEM. As control, EVs were inactivated by sonication (15 minutes at 60 kHz) and heating (40°C) to disrupt the membrane (iEV).

Analysis of the size distribution of EVs was performed using NanoSight LM10 (NanoSight Ltd, Minton Park, UK) [10].

Characterization of HLSC-derived EVs

EVs were characterized by cytofluorimetric analysis using fluorescein isothiocyanate (FITC), phycoerythrin (PE) or allophycocyanin (APC) conjugated antibodies against CD73, CD44, CD105, CD90, CD107, CD63, CD29, CD81, CD146 and HLA-class I. Conjugated mouse non-immune isotypic immunoglobulin G (IgG) (Miltenyi Biotec, Bergisch Gladbach, Germany) was used as control. Briefly, EVs (0.15 × 10^9 particles) were incubated for 15 minutes at 4°C with antibodies, then diluted 1 to 3 and immediately acquired as previously described [12,13]. Samples were acquired using Guava easyCyte Flow Cytometer (Millipore, Billerica, MA, USA) and analyzed with InCyte software.

We also performed fluorescence-activated cell sorting (FACS) analysis after absorption on beads. Briefly, EVs (10 μg) were incubated for 30 minutes to overnight in ice with 5 μl of latex beads (Aldeyde/sulphate LATEX 4MM, Invitrogen), then washed in PBS supplemented with 100 mM glycine and incubated for 30 minutes with the antibodies described above.

Protein content of the EV preparations was quantified by the Bradford method (Bio-Rad, Hercules, CA, USA).

Protein samples were separated by 4% to 15% gradient sodium dodecyl sulfate–polyacrylamide gel electrophoresis and subjected to immunoblotting with antibodies CD63, CD81, Alix (Santa Cruz Biotechnology, Santa Cruz CA, USA) and Hsp90 (Cell Signaling Technologies, Danvers, MA, USA). The protein bands were visualized with an enhanced chemiluminescence (ECL) detection kit and ChemiDoc™ XRS + System (BioRad). Cell and EV lysates were loaded at a concentration of 10 μg/well.

http://stemcellres.com/content/5/6/124
Preparation of HLSC-derived CM

HLSC-derived CM was produced as previously described [2]. Briefly, HLSC-CM was obtained from $20 \times 10^5$ cells/T75 cultured for 24 hours in RPMI deprived of FCS as for the collection of EVs. After two centrifugations at 3,000 g for 20 minutes to remove cell debris, cell-free CM were concentrated 25-fold by centrifugation at 2,700 g for 75 minutes, using Ultra-PL 3 ultrafiltration units (Amicon-Ultra; Millipore) with a 3-kDa molecular weight cutoff. A total of 250 μL of CM was obtained.

To evaluate the contribution of EVs in the biological effect of CM, in select experiments CM was depleted of EVs by ultracentrifugation (100,000 g for five hours); depletion was verified by NanoSight analyses, as described below.

Isolation and culture of murine tubular epithelial cells and in vitro experiments

Kidneys were obtained from healthy female C57 mice. Murine tubular epithelial cells (mTEC) were isolated, cultured and characterized for the presence of tubular markers and for the absence of endothelial and glomerular markers as previously described by Bruno et al. [6]. To determine the incorporation efficacy of HLSC-derived EVs, we incubated Dil labeled EVs, purified from 25,000 HLSCs, with 25,000 mTEC for five hours. The uptake of EVs was analyzed using confocal microscopy (Zeiss LSM 5 Pascal, Carl Zeiss, Oberkochen, Germany).

For proliferation experiments, mTECs were seeded at 4,000 cells/well into 96-well plates in 100 μl/well of (D)MEM low glucose with 2% FCS and in the presence of CM deprived of EVs, EVs and iEV derived from 8,000 HLSCs. DNA synthesis was detected as incorporation of 5-bromo-2’-deoxy-uridine (BrdU) into the cellular DNA after 48 hours of culture (Roche Applied Science, Mannheim, Germany).

For apoptosis experiments, mTECs were seeded at 25,000 cells/well into 24-well plates in (D)MEM low glucose without FCS in the presence of CM deprived of EVs, EVs and iEV derived from 50,000 HLSCs.

Cell death analysis was performed using the Muse Annexin V & Dead Cell Assay (Millipore) after 48 hours. The assay was performed according to the manufacturer’s protocols.

SCID mice model of AKI

Animal studies were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The protocol entitled: ‘Experimental models of renal regenerative therapies’ was approved

Figure 1 Effects of intravenous injection of HLSCs in AKI mice. (A) and (B) Creatinine and blood urea nitrogen (BUN) values on day 5 after glycerol administration in mice injected with vehicle alone, with HLSCs ($0.75 \times 10^5; 3.5 \times 10^5$) and in healthy (ctrl) SCID mice. Data are expressed as mean ± SD; ANOVA with Dunnet’s multicomparison test: $^*P<0.05$ HLSC-treated ($0.75 \times 10^5; 3.5 \times 10^5$) AKI mice versus vehicle-treated AKI mice. (C) Effect of HLSCs injection on renal morphology at day 5 after AKI induction. The number of hyaline casts and tubular necrosis observed under high power (original magnification: ×400) is expressed as mean ± SD. ANOVA with Dunnet’s multicomparison test: $^*P<0.05$ HLSC-treated ($0.75 \times 10^5; 3.5 \times 10^5$) AKI mice versus vehicle-treated AKI mice. (D) Representative micrographs of renal histology of healthy SCID mice (ctrl) and of AKI mice treated with vehicle alone or with different quantities of HLSCs ($0.75 \times 10^5; 3.5 \times 10^5$) and sacrificed at day 5. Original magnification: ×200. The typical aspect of hyaline cast formations and tubular necrosis are, respectively, shown by asterisks and head arrows. AKI, acute kidney injury; ANOVA, analysis of variance; HLSCs, human liver stem cells; SD, standard deviation.
on 22 November 2012 by the Committee on Bioethics of the University of Torino, Italy.

To evaluate the ability of HLSCs, HLSC-derived EVs or HLSC-derived CM to improve kidney injury, we induced AKI by intra-muscle injection of glycerol (Sigma) in SCID mice as previously described [6]. Mice were anesthetized with isoflurane and then injected with 50% glycerol in water, 8 ml/kg, half of the dose injected into each muscle of the inferior hind limbs. Glycerol induced myolysis and hemolysis, thereby exposing the kidney to large amounts of myoglobin and hemoglobin [6]. The peak of tubular injury was observed three days after glycerol injection. At this time, mice received different treatments. The following groups were studied: group 1, AKI mice intravenously (iv) injected with vehicle alone (n = 18); group 2, healthy mice iv injected with vehicle alone (n = 6); group 3, AKI mice iv injected with 0.75 x 10^5 (n = 4) or 3.5 x 10^5 (n = 7) HLSCs; group 4, AKI mice iv injected with concentrated CM HLSC-derived non EV depleted obtained from 3.5 x 10^5 HLSCs (n = 9), 10 x 10^5 HLSCs (n = 5), or 20 x 10^5 HLSCs (n = 10); group 5, AKI mice iv injected with CM HLSC-derived EV depleted (n = 11) obtained from 20 x 10^5 HLSCs; group 6, AKI mice iv injected with EVs produced by 3.5 x 10^5 HLSCs (n = 4; EV1) or with EVs derived from 10 x 10^5 HLSCs (n = 3; EV2). Sonicated EVs produced by 3.5 x 10^5 HLSCs were iv injected in AKI mice (group 7, n = 3).

Finally, Dil labeled EV1 were injected in AKI (group 8, n = 3) and in healthy mice (group 9, n = 3).

The iv injections were performed in 120 μL in the tail vein. In all experiments, cells cultured in T75 flasks until the 2 to 6 passage were detached by trypsin (0.5% w/v), washed, and resuspended in PBS.

To quantify proliferation of renal cells, BrdU (100 mg/Kg) was injected intraperitoneally for two consecutive days before the mice were killed.

![Figure 2](http://stemcellres.com/content/5/6/124)

**Figure 2** Renal cell proliferation in AKI mice treated with HLSCs. Quantification of BrdU (A) and PCNA (B) positive cells/hpf was performed in renal sections of AKI mice treated with vehicle alone or with different quantities of HLSCs and sacrificed after five days. BrdU was injected intraperitoneally for two consecutive days before mice were killed. Data are expressed as mean ± SD. ANOVA with Dunnet’s multicomparison test was performed: * P < 0.05 HLSC-treated AKI mice versus vehicle-treated AKI mice. Representative micrographs of PCNA (C) or BrdU (D) uptake staining performed on sections of kidneys five days after glycerol treatment (two days after vehicle or HLSC injection). Original magnification: ×400. AKI, acute kidney injury; ANOVA, analysis of variance; BrdU, 5-bromo-2′-deoxy-uridine; HLSCs, human liver stem cells; PCNA, proliferating cell nuclear antigen; SD, standard deviation.
Renal function
Blood samples for measurement of blood urea nitrogen (BUN) and plasma creatinine were collected five days after glycerol-induced AKI. Plasma creatinine was measured using a colorimetric microplate assay based on the Jaffe reaction (Quantichrom Creatinine Assay, BioAssay Systems, Hayward, CA, USA). BUN was measured by direct quantification of plasma urea with a colorimetric assay kit according to the manufacturer’s protocol (Quantichrom Urea Assay, BioAssay Systems).

Morphological studies
For renal histology, 5 μm-thick paraffin kidney sections were routinely stained with hematoxylin and eosin (H&E, Merck, Darmstadt, Germany) for microscopic examination.
Luminal hyaline casts and cell necrosis (denudation of tubular basement membrane) were assessed in non-overlapping fields (10 for each section) using a 40× objective (high power field, HPF). The number of casts and tubular profiles showing necrosis were recorded in a single-blind fashion.
Immunohistochemistry for detection of proliferation of tubular cells was performed as described previously [6]. Kidney sections were subjected to antigen retrieval, and slides were blocked and labeled with 1:25 dilution of monoclonal anti BrdU antibody (Dako Cytomation, Milan, Italy), or 1:400 of monoclonal anti-proliferating cell nuclear antigen (PCNA, Santa Cruz Biotechnology). Immunoperoxidase staining was performed using 1:300 dilution of anti-mouse horseradish peroxidase (HRP, Pierce, Rockford, IL, USA). Scoring for BrdU- and PCNA-positive cells was carried out by counting the number of positive nuclei per HPF (40x) in 10 randomly chosen sections of kidney cortex.

Confocal microscopy analysis was performed on frozen sections for localization of Dil-labeled EVs in kidneys of healthy and AKI mice. Sections were blocked and labeled with rabbit anti laminin (Sigma) (1:100 dilution). Omission of the primary antibodies or substitution with non immune rabbit IgG was used as control. Alexa Fluor 488 anti-rabbit (Molecular Probes) was used as secondary antibody.

Statistical analysis
Results are expressed as mean ± standard deviation (SD). Statistical analysis was performed by using the t test, analysis of variance (ANOVA) with Newmann-Keuls or ANOVA with Dunnet’s multicomparison tests when appropriate. A P value of <0.05 was considered significant.

Results
HLSCs favor AKI recovery
To determine whether HLSCs were capable of favoring renal regeneration, we induced AKI in SCID mice with an intramuscular injection of hypertonic glycerol. At day 3 after injury, $0.75 \times 10^5$ and $3.5 \times 10^5$ HLSCs were injected intravenously into AKI mice. Figure 3 presents the results of the study. 

Figure 3 Effects of intravenous injection of HLSC-derived CM into AKI mice. Creatinine (A) and BUN (B) were measured in mice treated with vehicle alone and in HLSC-derived CM-treated mice five days after glycerol injection and in healthy control (ctrl) mice. Data are expressed as mean ± SD; ANOVA with Dunnet’s multicomparison test: *P <0.05 HLSC-derived CM-treated AKI mice versus vehicle-treated AKI mice. (C) Comparison of HLSC-derived CM injections on tubular morphology at day 5 after AKI induction. Data are expressed as mean ± SD of hyaline cast and necrotic tubules observed under high power (original magnification: x400). ANOVA with Dunnet’s multicomparison test: *P <0.05 HLSC-derived CM-treated AKI mice versus vehicle-treated AKI mice. (D) Representative micrographs of renal histology of healthy SCID mice and of AKI mice treated with vehicle alone or injected intravenously with concentrated CM derived from different quantities of HLSCs (CM (3.5 x 10^5), CM (10 x 10^5), CM (20 x 10^5)) (original magnification: x200). AKI, acute kidney injury; ANOVA, analysis of variance; BUN, blood urea nitrogen; CM, conditioned medium; HLSCs, human liver stem cells; SCID, severe–combined immune-deficient; SD, standard deviation.
injected in AKI mice that were sacrificed at day 5. In AKI mice significant increases in plasma levels of creatinine and BUN were observed at day 3 (Figure 1A and B). Mice injected with $0.75 \times 10^5$ and $3.5 \times 10^5$ HLSCs exhibited, at day 5 (48 hours after treatment), a significant reduction of creatinine levels (Figure 1A and B) at both cells concentrations, whereas a significant reduction of BUN was observed only with $3.5 \times 10^5$ HLSCs (Figure 1A and B). Histological analysis confirmed the functional results (Figure 1C and D). The morphological alterations observed in SCID mice with AKI included tubular hyaline cast formation and tubular necrosis (Figure 1D). AKI mice treated with $0.75 \times 10^5$ and $3.5 \times 10^5$ HLSCs had a significantly lower number of hyaline cast formations and lower number of necrotic tubules compared with AKI mice treated with vehicle alone (Figure 1C and D).

The effect of HLSC treatment on tubular cell proliferation was investigated by studying the expression of PCNA and the uptake of BrdU by tubular cells in treated or untreated AKI mice (Figure 2). Proliferation of tubular cells was significantly increased in mice treated with $3.5 \times 10^5$ HLSCs with respect to AKI mice treated with vehicle alone (Figure 2). The lower dose of HLSCs ($0.75 \times 10^5$) failed to stimulate tubular proliferation.

CM reproduced the protective effect of HLSCs
In order to study the effect of paracrine factors produced by HLSCs, different preparations of concentrated CM derived from $3.5 \times 10^5$, $10 \times 10^5$ and $20 \times 10^5$ HLSCs were injected in AKI mice (Figure 3). At day 5 after glycerol injection, treatments with CM resulted in significant decreases of creatinine and BUN levels (Figure 3A and B) compared to mice treated with vehicle alone. Also, tubular injury improved in mice treated with CM (Figure 3C and D). In particular, hyaline tubular casts and the degree of necrosis were reduced with respect to mice given vehicle alone. CM produced by $3.5 \times 10^5$ HLSCs failed to attenuate tubular injury (Figure 3C and D).

Concentrated CM contained $71.0 \pm 7.0 \times 10^9$ EVs/ml as detected by Nanosight. In order to study the contribution of EVs in the regenerative properties of CM, EV-depleted CM obtained from $20 \times 10^5$ cells was used. Depletion of EVs did not abrogate but significantly reduced the functional and morphological recovery (Figure 4A-C). More evident was the effect on proliferation. Only EV-containing CM was able to stimulate proliferation as detected by PCNA expression and BrdU incorporation (Figure 4D and E).

**Figure 4** Effect of concentrated CM depleted of EVs on AKI recovery. Creatinine (A) and BUN (B) were measured in AKI mice treated with vehicle alone or with CM depleted (AKI + CM w/o EVs) or not of EVs (AKI + CM + EVs) five days after glycerol injection. Data are expressed as mean ± SD; Analysis of variance with Newmann-Keuls multicomparison test was performed; *P < 0.05 CM-treated AKI mice versus vehicle-treated AKI mice; **P < 0.05 CM + EVs-treated AKI mice versus CM w/o EVs-treated AKI mice. (C) Comparison of tubular morphology in AKI mice injected with HLSC-CM depleted or not of EVs. Data are expressed as mean ± SD of hyaline cast formations and tubular necrosis observed under high power (original magnification: x400). Analysis of variance with Newmann-Keuls multicomparison test; *P < 0.05 CM = treated AKI mice versus vehicle-treated AKI mice, **P < 0.05 CM + EV-treated AKI mice versus CM w/o EV-treated AKI mice. Quantification of PCNA (D) and BrdU (E) positive cells/hpf in AKI mice treated with vehicle alone or CM with or without (w/o) EVs and CM + EVs and sacrificed after five days. BrdU was injected intraperitoneally for two successive days before mice were killed. Data are expressed as mean ± SD. ANOVA with Dunnet’s multicomparison test was performed; *P < 0.05 CM + EV-treated AKI mice versus vehicle-treated AKI mice; AKI, acute kidney injury; ANOVA, analysis of variance; BrdU, 5-bromo-2′-deoxy-uridine; BUN, blood urea nitrogen; CM, conditioned medium; EV, extracellular vesicles; HLSCs, human liver stem cells; hpf, high power field; PCNA, proliferating cell nuclear antigen; SD, standard deviation; w/o, without.
HLSC-derived EV characterization and *in vitro* effects

By nanoparticle tracking analysis (NTA) the EV population appeared heterogeneous in size distribution (Figure 5). The mean size of EVs was $174 \pm 64$ nm, with the presence of small EVs with a diameter of about 60 nm (Figure 5A).

The expression of some classical exosomal markers (CD81, CD63, Alix and Hsp90) was detected by Western blot analysis (Figure 5B).

Guava FACS analyses showed the presence of several mesenchymal surface markers characteristic of HLSCs.

---

**Figure 5** Characterization of HLSC-derived EVs surface markers and NTA analyses. (A) Nanosizer analysis of purified HLSC-derived EVs: curve 1 shows the relationship between particle distribution (left Y axis) and particle size (X axis); curve 2 shows the correlation between cumulative percentage distribution of particles (percentile in right Y axis) and particle size (X axis). Mean size and particle concentration values were calculated by Nanoparticle Tracking Analysis (NTA). (B) Representative Western blot analysis of exosomal markers CD63, CD81, Alix and Hsp90 expressed by HLSCs and derived EV (10 μg protein/well). (C-D) Representative FACS analyses of the expression of classical mesenchymal (C) and exosomal markers (D) by HLSC-derived EVs. Dot lines indicate the isotopic controls. Three different EV preparations were tested with similar results. EVs, extracellular vesicles; FACS, fluorescence-activated cell sorting; HLSC, human liver stem cell.
such as CD29, CD90, CD44 and CD73 and of exosomal markers CD81 and CD107 (Figure 5C and D). Similar results were obtained by FACS analyses performed on vesicles pre-absorbed on beads (not shown).

To evaluate the ability of EV-HLSCs to be incorporated by mTEC, Dil labeled EVs were incubated with the cells. EV-HLSCs were incorporated by mTEC, as observed by confocal microscopy after five hours of incubation at 37°C (Figure 6A).

To understand the possible different effect of CM and EVs derived from HLSCs on cell proliferation and apoptosis, in vitro experiments were performed. Incubation of

**Figure 6 Up-take of EVs by murine tubular epithelial cells.** (A) Representative micrograph of incorporation of EVs collected from HLSCs stained with Dil (red) by mTEC after five hours of incubation. Original magnification: ×630. Nuclei were stained with Hoechst. Three experiments were performed with similar results. (B) Quantification of proliferation rate by BrdU incorporation assay. mTEC (4,000 cells/well) were treated with vehicle, EV, CM and iEV derived from 8,000 HLSCs. Experiments were conducted in triplicate. Data are expressed as mean ± SD; ANOVA with Dunnet’s multicomparison test was performed: *P <0.05 EV versus vehicle. (C) Evaluation of apoptosis of mTEC (25,000 cells/well) treated with vehicle, CM, EV and iEV derived from 50,000 HLSCs by Muse Annexin V & Dead Cell Assay. Data are expressed as mean ± SD; ANOVA with Newmann-Keuls multicomparison test was performed: *P <0.05 EV and CM versus vehicle; #P <0.05 CM versus EV. ANOVA, analysis of variance; BrdU, 5-bromo-2′-deoxy-uridine; CM, conditioned medium; EV, extracellular vesicles; HLSCs, human liver stem cells; iEV, inactivated extracellular vesicles; mTEC, murine tubular epithelial cells; SD, standard deviation.
mTECs with EVs promoted significant cell proliferation with respect to control cells incubated with vehicle alone or with CM deprived of EVs or with iEVs (Figure 6B). Moreover, incubation of mTECs with CM completely inhibited apoptosis induced by serum deprivation (Figure 6C), indicating the relevant anti-apoptotic effect of paracrine factors present in CM. EVs also significantly reduced the apoptosis in mTEC but were less effective than CM (Figure 6C).

No stimulation of proliferation and protection from apoptosis was observed with iEVs.

HLSC-derived EVs mediated the improvement of renal function and morphology in AKI and stimulated tubular cell proliferation

Labeled EVs, produced by $3.5 \times 10^5$ HLSCs (EV1), were injected in healthy and AKI mice; five hours after the injection mice were sacrificed and kidneys recovered for analysis. Labeled EVs accumulated preferentially within injured kidneys (Figure 7A and B) and were detectable within tubules and glomeruli. Two concentrations of purified EVs (EV1 = $1.88 \pm 0.6 \times 10^9$ particles produced by $3.5 \times 10^5$ HLSCs; EV2 = $5.53 \pm 2.15 \times 10^9$ particles pro-

**Figure 7** Effects of intravenous injection of purified EVs released from HLSCs. (A-B) Representative micrographs of renal tissues of healthy mice (A) and of AKI mice (B) treated with Dil labeled EVs (red), five hours after the injection. Original magnification: x630. Nuclei were stained in blue with Hoechst and laminin in green. (C) Creatinine and (D) BUN values on day 5 after glycerol administration. Data are expressed as mean ± SD; ANOVA with Dunnett’s multicomparison test was performed. *P < 0.05 EV-treated AKI mice versus vehicle-treated AKI mice. (E) Representative micrographs of renal histology of control healthy mice (ctrl) or AKI mice at day 5 after glycerol administration intravenously injected with vehicle alone (AKI + vehicle) or with EVs derived from $3.5 \times 10^7$ HLSCs (EV1) or from $10 \times 10^5$ HLSCs (EV2). Original magnification: x400. (F) Comparison of HLSC-derived EV injection on tubular morphology at day 5 after AKI induction. Data are expressed as mean ± SD of hyaline casts and necrotic tubules observed under high power (original magnification: x400). ANOVA with Dunnet’s multicomparison test was performed: *P < 0.05 EV-treated AKI mice versus vehicle-treated AKI mice. (G) Quantification of PCNA-positive cells/hpf in AKI mice untreated or treated with HLSC-derived EVs after five days of AKI. Data are expressed as mean ± SD; ANOVA with Dunnet’s multicomparison test: *P < 0.05 EV-treated AKI mice versus vehicle-treated AKI mice. AKI, acute kidney injury; ANOVA, analysis of variance; BUN, blood urea nitrogen; CM, conditioned medium; EV, extracellular vesicles; HLSCs, human liver stem cells; hpf, high power field; PCNA, proliferating cell nuclear antigen; SD, standard deviation.
duced by $10 \times 10^5$ HLSCs) were injected three days after induction of AKI. At day 5 after glycerol injection, EVs significantly decreased creatinine and BUN plasma levels (Figure 7C and D) and improved tubular injury (Figure 7E and F) when compared with vehicle alone. The increased expression of PCNA by tubular cells suggested that EVs stimulated proliferation (Figure 7G).

The injection of iEV did not accelerate the recovery of the tubular damage (Figure 7C and D).

**Discussion**

In the present study, we demonstrated that HLSCs favor recovery of glycerol-induced AKI in SCID mice. Moreover, CM of HLSCs mimicked the effect of the cells. EV depletion significantly reduced the healing properties of CM. Purified EVs had the same effect as HLSCs suggesting that HLSC-derived EVs are responsible for the improved renal function.

Several studies demonstrated the beneficial effect of stem cells in the murine experimental model of AKI [14–16]. Many studies focused on the exogenous administration of MSCs because of their regenerative potential and tropism for damaged tissues [15,17]. The infusion of murine MSCs has been shown to accelerate kidney recovery in cisplatin- or glycerol-induced AKI [14,15]. In ischemia-reperfusion injury, rat MSCs protected from ischemic acute renal failure through the production of factors with anti-apoptotic and mitogenic activity [18]. The low number of MSCs engrafted in the injured kidney in the face of the strong functional recovery raised the hypothesis that soluble mediators may explain the renoprotective effect of MSCs [19]. It has been suggested that EVs may interact with target cells and transfer functional proteins, micro-RNAs and mRNAs that may modify their phenotype [9,20]. The biological effect of human MSC-derived EVs has been shown in several xenogenic models suggesting that carried biological molecules are also active in different species [6,7,21–24].

In a recent study, Bruno et al. [6] documented that EVs produced by MSCs shuttled a specific subset of cellular mRNAs that stimulate survival and proliferation of injured tubular cells. Furthermore, in a lethal model of AKI induced by cisplatin, we found that EVs released by MSCs enhanced survival and that multiple injections of EVs restored normal histology and renal function at day 21 [10].

On the other hand, we found that HLSC paracrine mediators also exert biological activities [2,11]. We demonstrated that HLSC-derived EVs stimulated proliferation and favored regeneration in a model of 70% hepatectomy in rats by a mechanism involving the transfer of specific mRNA subsets [11]. Moreover, the injection of HLSC-derived CM significantly attenuates mouse mortality in a model of fulminant liver failure induced by D-galactosamine and lipopolysaccharide in SCID mice [2].

In the present study, we found that iv injection of HLSCs at a concentration of $3.5 \times 10^5$ cells/mouse in SCID mice with glycerol-induced AKI protected mice from tubular injury and functional impairment. HLSCs promoted histological and functional amelioration of renal damage; moreover, HLSCs stimulated proliferation of tubular epithelial cells. When we injected CM derived from HLSCs in injured SCID mice, we observed an improvement of function and morphological recovery of kidney in comparison with mice treated with vehicle alone. However, when CM was depleted of EVs by ultracentrifugation, CM failed to stimulate tubular proliferation. In contrast, purified EVs reproduced the same biological effect as HLSCs promoting AKI recovery. In *vitro* HLSC-derived EVs stimulated proliferation and inhibited apoptosis of murine renal tubular cells.

**Conclusions**

The results of the present study indicate that HLSCs have a healing action in a model of AKI characterized by extensive damage of proximal tubular epithelial cells. HLSC treatment improved renal function and stimulated proliferation of tubular epithelial cells thus favoring recovery. CM mimicked the effect of HLSCs suggesting a paracrine mechanism involving EVs released by these cells. In fact, CM depleted of EVs abated the beneficial effect and purified EVs exhibited the same regenerative effect as HLSCs.

**Abbreviations**

(D)MEM: (Dulbecco’s) modified Eagle’s medium; AKI: acute kidney injury; BrdU: 5-bromo-2′-deoxy-uridine; BUN: blood urea nitrogen; CM: conditioned medium; EVs: extracellular vesicles; FACs: fluorescence-activated cell sorting; FCS: fetal calf serum; HLSCs: human liver stem cells; HPF: high power field; iEVs: inactivated extracellular vesicles; MSCs: mesenchymal stem cells; mTEC: murine tubular epithelial cells; NTA: nanoparticle tracking analysis; PBS: phosphate-buffered saline; PCNA: proliferating cell nuclear antigen; SCID: severe-combined immune-deficient mice.

**Competing interests**

CT (Fresenius Medical Care) is employed by commercial companies and contributed to the study as a researcher. MBH, CT and GC are named inventors in related patents. The other authors declare that they have no competing interests.

**Authors’ contributions**

MBH, SB, CG and MT contributed to conception and design, acquisition of data and analysis and interpretation of data. VC, CT and GC contributed to the analysis of data. MBH, SB, CG and GC have been involved in drafting the manuscript. VC and CT critically revised the manuscript. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

**Acknowledgements**

The technical assistance of Federica Antico and Claudia Cavallari is gratefully acknowledged.

**Author details**

1 Translational Center for Regenerative Medicine and Molecular Biotechnology Center, University of Torino, Via Nizza 52, 10126 Torino, Italy.
Cell Commun Signal

Human liver stem cells and kidney repair. Stem Cell Res Ther 24: 124. doi:10.1186/scrt514

Cite this article as: Herrera Sanchez et al. Human liver stem cells and derived extracellular vesicles improve recovery in a murine model of acute kidney injury. Stem Cell Research & Therapy 2014 5:124.

Submitted your manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

References

1. Herrera MB, Bruno S, Buttiigliere S, Tetta C, Gatti S, Deregibus MC, Bussolati B, Camussi G: Isolation and characterization of a stem cell population from adult human liver. Stem Cells 2006, 24:2840–2850.

2. Herrera MB, Fonsato V, Bruno S, Grange C, Gilbo N, Romagnoli R, Tetta C, Camussi G: Human liver stem cells improve liver injury in a model of fulminant liver failure. Hepatology 2013, 57:311–319.

3. Camussi G, Deregibus MC, Cantaluppi V: Role of stem-cell-derived microvesicles in the paracrine action of stem cells. Biochim Soc Trans 2013, 41:283–287.

4. Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C: Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005, 289:31–42.

5. Bi B, Schmitt R, Iralova M, Nishio H, Cantley LG: Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 2007, 18:2486–2494.

6. Bruno S, Grange C, Deregibus MC, Calogero RA, Savolitto S, Collino F, Morando L, Busca A, Falda M, Bussolati B, Tetta C, Camussi G: Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009, 20:1053–1067.

7. Gatti S, Bruno S, Deregibus MC, Sordi A, Cantaluppi V, Tetta C, Camussi G: Microvesicles derived from human adult mesenchymal stem cells protect against ischemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 2011, 26:1474–1483.

8. De Broe ME, Wieme RJ, Logghoe GN, Roofs F: Spontaneous shedding of plasma membrane fragments by human cells in vivo and in vitro. Clin Chim Acta 1977, 81:237–245.

9. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ: Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006, 20:1487–1495.

10. Bruno S, Grange C, Collino F, Deregibus MC, Cantaluppi V, Biancone L, Tetta C, Camussi G: Microvesicles derived from human mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One 2012, 7(10):e43115.

11. Herrera MB, Fonsato V, Gatti S, Deregibus MC, Sordi A, Cantarella D, Calogero R, Bussolati B, Tetta C, Camussi G: Human liver stem cell-derived microvesicles accelerate hepatic regeneration in hepatocstromed rats. J Cell Mol Med 2010, 14:1605–1618.

12. Grange C, Tapparo M, Bruno S, Chatterjee D, Quesenberry PJ, Tetta C, Camussi G: Biodistribution of stem cell-derived extracellular vesicles in a model of acute kidney injury monitored by optical imaging. Int J Mol Med 2014, 33:1055–1063.

13. Lopatina T, Bruno S, Tetta C, Kalinha N, Porta M, Camussi G: Platelet-derived growth factor regulates the secretion of extracellular vesicles by adipose mesenchymal stem cells and enhances their angiogenic potential. Cell Commun Signal 2014, 12:26.

14. Morigi M, Imberti B, Zoa C, Coma D, Tomasoni S, Abbate M, Rottoli D, Angiullietti S, Berini A, Perico N, Alisson M, Remuzzi G: Mesenchymal stem cells are renoprotective, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004, 15:1794–1804.

15. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G: Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004, 14:1035–1041.

16. Morigi M, Berini A: Mesenchymal stem cells and kidney repair. Nephrol Dial Transplant 2013, 28:789–793.

17. Herrera MB, Bussolati B, Bruno S, Morando L, Maurillo-Romanazzi G, Sanvito F, Stamenkovic I, Biancone L, Camussi G: Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 2007, 72:430–441.

18. Lange C, Tögel F, Ittrich H, Clayton F, Nolte-Ernsting C, Zander AR, Westenfelder C: Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int 2005, 68:1613–1617.

19. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L: Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 2010, 78:838–848.

20. Janowska-Wieczorek A, Majka M, Kijowski J, Baj-Krzyworzeka M, Rea C, Turner AR, Ratajczak J, Emerson SG, Kowalska MA, Ratajczak MZ: Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. Blood 2001, 98:3143–3149.

21. Ban S, Zhang L, Duan L, Wang X, Yin Y, Yu H: Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. J Mol Med 2014, 92:367–397.

22. Zhu YG, Feng XM, Abbott J, Fang YH, Hao Q, Monsel A, Qu JM, Matthay MA, Lee JW: Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells 2014, 32:116–125.

23. Zhou Y, Xu H, Xu W, Wang B, Wu H, Tao Y, Zhang B, Wang M, Mao F, Yan Y, Gao S, Gu H, Zhu W, Qian H: Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res Ther 2013, 4:34.

24. Zou X, Zhang G, Cheng Z, Yin D, Du T, Ju G, Miao S, Liu G, Lu M, Zhu Y: Microvesicles derived from human Wharton’s Jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CXCL1. Stem Cell Res Ther 2014, 5:40.